

CITATION REPORT

List of articles citing

Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019

DOI: 10.1001/jamanetworkopen.2022.16183
JAMA Network Open, 2022, 5, e2216183.

Source: <https://exaly.com/paper-pdf/148433858/citation-report.pdf>

Version: 2024-04-18

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Beschleunigte Zulassungsverfahren: Status quo, Probleme und Reformbedarf. 2022 , 25, 12-15		0
7	Assessment of the delay in novel anticancer drugs between China and the United States: a comparative study of drugs approved between 2010-2021.		0
6	No new drugs in medicine. New nomenclature for monoclonal antibodies.		0
5	Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries. 2023 , 23,		0
4	From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit. 2023 , 24, e150-e160		0
3	The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020. 2023 , 152, 2474-2484		0
2	Modernising the US FDA's Accelerated Approval pathway. 2023 , 24, 203-205		0
1	ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology.		0